Close

Cytori Therapeutics (CYTX) Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin

April 30, 2018 8:35 AM EDT Send to a Friend
Cytori Therapeutics, Inc. (Nasdaq: CYTX) (“Cytori” or “the Company”) today provided an update on its plans for US manufacturing and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login